Gilead's Hep C Drug: $84,000 in U.S.; $900 in India

Aug 07, 2014

As reported by the Times of India, U.S.-based Gilead Sciences will introduce Sovaldi, its breakthrough hep C treatment, in India at close to a 99% discount of the U.S. price.

According to Gilead, the India pricing -- $900 per patient -- reflects the drugmaker's three basic pricing tiers, based on a country’s per capita income and hepatitis C prevalence.

The the U.S. FDA approved Gilead's Sovaldi to treat chronic hepatitis C virus infection in early December 2013. Gilead's plan to bring lower-cost Sovaldi to other countries has further fueled U.S. controversy, where Sovaldi costs $84,000 for the 12-week regimen, and become a prime example for the growing national debate over the rising cost of prescription drugs.

Read the WSJ blog

 



Join the discussion

We welcome your thoughtful comments. Please comply with our Community rules.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments